DrugPatentWatch Database Preview
Details for Patent: 7,439,241
Which drugs does patent 7,439,241 protect, and when does it expire?
This patent has sixty-four patent family members in twenty-four countries.
Summary for Patent: 7,439,241
Title: | Compounds, formulations, and methods for treating or preventing rosacea |
Abstract: | In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms. |
Inventor(s): | DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ) |
Assignee: | Galderma Laboratories, Inc. (Fort Worth, TX) |
Application Number: | 10/853,585 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 7,439,241
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galderma Labs Lp | MIRVASO | brimonidine tartrate | GEL;TOPICAL | 204708-001 | Aug 23, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 7,439,241
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
8,859,551 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | ➤ Sign Up |
8,557,817 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | ➤ Sign Up |
8,410,102 | Methods and compositions for treating or preventing erythema | ➤ Sign Up |
8,426,410 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 7,439,241
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 530185 | ➤ Sign Up | |||
Australia | 2004242967 | ➤ Sign Up | |||
Australia | 2005247467 | ➤ Sign Up | |||
Australia | 2011231543 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |